U.S. FDA Approves Celltrion of S. Korea To Make Orencia for Bristol-Myers (S. Korea)
This article was originally published in PharmAsia News
Executive Summary
The U.S. FDA approved South Korea's Celltrion to make a rheumatoid arthritis drug for Bristol-Myers Squibb. Under the plan, biotech Celltrion is to be the contract manufacturer of Orencia, a biologic agent for treating the disease. Celltrion says Bristol-Myers expects the South Korean plant to help it meet long-term demand for the drug. (Click here for more